Squarepoint’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-107,053
| Closed | -$450K | – | 4202 |
|
|
2023
Q1 | $450K | Buy |
107,053
+75,016
| +234% | +$389K | ﹤0.01% | 2363 |
|
|
2022
Q4 | $193K | Buy |
+32,037
| New | +$175K | ﹤0.01% | 2803 |
|
|
2022
Q2 | – | Sell |
-171,161
| Closed | -$799K | – | 3632 |
|
|
2022
Q1 | $799K | Buy |
+171,161
| New | +$510K | ﹤0.01% | 1718 |
|
|
2021
Q3 | – | Sell |
-72,325
| Closed | -$181K | – | 3762 |
|
|
2021
Q2 | $181K | Sell |
72,325
-125,186
| -63% | -$300K | ﹤0.01% | 2871 |
|
|
2021
Q1 | $575K | Buy |
+197,511
| New | +$645K | ﹤0.01% | 1917 |
|
|
2019
Q4 | – | Sell |
-89,228
| Closed | -$75K | – | 2987 |
|
|
2019
Q3 | $75K | Buy |
89,228
+52,803
| +145% | +$40.3K | ﹤0.01% | 2217 |
|
|
2019
Q2 | $31K | Buy |
+36,425
| New | +$33.6K | ﹤0.01% | 2305 |
|
|
2018
Q3 | – | Sell |
-13,102
| Closed | -$65K | – | 2386 |
|
|
2018
Q2 | $65K | Buy |
+13,102
| New | +$57.3K | ﹤0.01% | 1676 |
|
|
2017
Q1 | – | Sell |
-5,690
| Closed | -$23K | – | 2204 |
|
|
2016
Q4 | $23K | Buy |
+5,690
| New | +$23.6K | ﹤0.01% | 1725 |
|
|
2016
Q3 | – | Sell |
-9,370
| Closed | -$32K | – | 1486 |
|
|
2016
Q2 | $32K | Buy |
+9,370
| New | +$43K | ﹤0.01% | 1048 |
|
|
2016
Q1 | – | Sell |
-1,480
| Closed | -$18K | – | 1682 |
|
|
2015
Q4 | $18K | Buy |
+1,480
| New | +$19.8K | ﹤0.01% | 1209 |
|
Other funds holding CTIC
Squarepoint's CTIC Position: Q2 2023 in Review
Squarepoint sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 107,053 shares — an estimated $450K sold.
Squarepoint first reported a position in CTIC in Q4 2015 and held it in 11 quarters. The position peaked at $799K in Q1 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- Squarepoint reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- Squarepoint sold 107,053 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $450K.
- Squarepoint first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2015 and held it in 11 quarters.
- Squarepoint's CTI BioPharma Corp. (DE) Common Stock position peaked at $799K in Q1 2022.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on Squarepoint's 13F filing for Q2 2023, filed 14 Aug 2023.